NorthStar Medical Radioisotopes and GE Healthcare have signed an exclusive agreement for the manufacturing and distribution of iodine-123 capsules in the United States, NorthStar announced recently.
Iodine-123 is a radioactive form of iodine that’s used in diagnosing thyroid cancer.
According to a release, GE Healthcare’s Pharmaceutical Diagnostics unit will manufacture and supply NorthStar with these capsules under the NorthStar label using a new production system at its facility in Illinois.
After the receipt of the required regulatory approvals, Beloit-based NorthStar will retain exclusive U.S. marketing and distribution rights for the I-123 capsules.
“This exclusive sales and manufacturing agreement marks NorthStar’s strong and growing relationship with GE Healthcare, and we look forward to working with the company in meeting the needs of radiopharmacy customers and the patients we all serve,” NorthStar Medical Radioisotopes CEO Stephen Merrick said in a statement.
The financial terms of the deal were not disclosed.
See more at Madison Startups: https://www.madisonstartups.com/northstar-ge-healthcare-sign-exclusive-agreement/
See the release: https://www.northstarnm.com/northstar-medical-radioisotopes-and-ge-healthcare-sign-exclusive-u-s-manufacturing-and-distribution-agreement/
;
